Daiichi Sankyo Company, Limited (DSNKY)
OTCMKTS · Delayed Price · Currency is USD
24.48
+0.13 (0.53%)
Aug 14, 2025, 1:44 PM EDT
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 19,765 employees as of March 31, 2025. The number of employees increased by 1,039 or 5.55% compared to the previous year.
Employees
19,765
Change (1Y)
1,039
Growth (1Y)
5.55%
Revenue / Employee
$674,943
Profits / Employee
$103,756
Market Cap
44.89B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 19,765 | 1,039 | 5.55% |
| Mar 31, 2024 | 18,726 | 1,291 | 7.40% |
| Mar 31, 2023 | 17,435 | 977 | 5.94% |
| Mar 31, 2022 | 16,458 | 425 | 2.65% |
| Mar 31, 2021 | 16,033 | 685 | 4.46% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Tian'an Technology Group | 8 |
| Elite Pharmaceuticals | 68 |
| Glass House Brands | 374 |
| Northwest Biotherapeutics | 25 |
| American Oncology Network | 1,914 |
| CytoDyn | 13 |
| Silence Therapeutics | 116 |
Daiichi Sankyo Company News
- 13 days ago - Daiichi Sankyo Company, Limited (DSKYF) Q1 FY2025 Earnings Call Transcript - Seeking Alpha
- 13 days ago - Daiichi Sankyo has inventory buffer, will expand production capacity in Ohio to mitigate US tariffs - CFO - CNBC
- 14 days ago - Daiichi Sankyo reports Q1 results - Seeking Alpha
- 4 weeks ago - AstraZeneca, Daiichi Sankyo get U.S. breakthrough therapy status for Enhertu - Seeking Alpha
- 4 weeks ago - ENHERTU® Plus Pertuzumab Granted Breakthrough Therapy Designation in the U.S. as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga
- 7 weeks ago - Daiichi Sankyo, AstraZeneca gets U.S. approval for Datroway - Seeking Alpha
- 7 weeks ago - DATROWAY® Approved in the U.S. as First TROP2 Directed Therapy for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer - Benzinga
- 2 months ago - Targeted cancer drugs may replace chemo for some patients and drugmakers say they're getting closer - CNBC